Zhejiang Tianyu Pharmaceutical Co., Ltd. Stock

Equities

300702

CNE1000034X1

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-05-07 pm EDT 5-day change 1st Jan Change
20.56 CNY +2.24% Intraday chart for Zhejiang Tianyu Pharmaceutical Co., Ltd. +7.53% -5.30%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2024 * 2.91B 402M Sales 2025 * 3.35B 464M Capitalization 7.07B 979M
Net income 2024 * 277M 38.34M Net income 2025 * 321M 44.44M EV / Sales 2024 * 2.43 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 2.11 x
P/E ratio 2024 *
25.8 x
P/E ratio 2025 *
22.3 x
Employees 5,070
Yield 2024 *
0.54%
Yield 2025 *
1.07%
Free-Float 38.19%
More Fundamentals * Assessed data
Dynamic Chart
China Approves Tianyu Pharma's Heart Medication MT
Zhejiang Tianyu Pharmaceutical Co., Ltd. Announces Profit Distribution Proposal for 2023 CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Zhejiang Tianyu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on January 24, 2024. CI
Zhaoxin Liaowang No. 1 Private Securities Investment Fund managed by Jiangsu Zhaoxin Private Fund Management Co., Ltd. entered into a share transfer agreement to acquire 6.19% stake in Zhejiang Tianyu Pharmaceutical Co., Ltd. from Ganzhou Zhenhan Venture Capital Co., Ltd. for CNY 310 million. CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 50 million worth of its shares. CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Tianyu Pharmaceutical Unit Passes US FDA's On-Site Inspection MT
Tianyu Pharma Unit Passes US FDA On-Site Inspection MT
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Zhuhai Rundu Pharma Gets Supplementary Application Approval For Hypertension Drug MT
Raw Drug Material of Tianyu Pharma's Unit Passes Regulatory Evaluation MT
Zhejiang Tianyu Pharmaceutical Co., Ltd. announced that it expects to receive CNY 1.4 billion in funding CI
More news
1 day+2.24%
1 week+7.53%
Current month+7.53%
1 month+31.96%
3 months+21.73%
6 months-10.14%
Current year-5.30%
More quotes
1 week
19.17
Extreme 19.17
20.75
1 month
16.02
Extreme 16.02
20.75
Current year
13.16
Extreme 13.16
21.68
1 year
13.16
Extreme 13.16
28.00
3 years
13.16
Extreme 13.16
59.52
5 years
13.16
Extreme 13.16
72.02
10 years
7.51
Extreme 7.5111
72.02
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 03-01-31
Director of Finance/CFO 39 21-04-18
Director/Board Member 52 -
Members of the board TitleAgeSince
Director/Board Member 49 22-05-12
Chief Executive Officer 61 03-01-31
Director/Board Member 55 03-01-31
More insiders
Date Price Change Volume
24-05-08 20.56 +2.24% 4,176,358
24-05-07 20.11 +1.87% 3,841,556
24-05-06 19.74 +3.24% 4,301,840
24-04-30 19.12 +3.63% 5,963,600

End-of-day quote Shenzhen S.E., May 07, 2024

More quotes
Zhejiang Tianyu Pharmaceutical Co Ltd is a company mainly engaged in research and development, production and sales of chemical raw materials. The Company operates three segments. The Pharmaceutical Intermediates segment include hypertension drugs raw materials, anti-asthma drugs raw materials and anticoagulant drugs raw materials. The Active Pharmaceutical Ingredients (API) segment is engaged in production of high blood pressure drug intermediates, anti-asthma drug intermediates and antiviral drug intermediates. The Company also operates Other segment. The Company sells its products to both domestic and international markets, including Europe, the United States, Japan, South Korea and so on.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
20.56 CNY
Average target price
22.6 CNY
Spread / Average Target
+9.92%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300702 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW